Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Clinical trial NCT02254265 · COMPLETED
Trial details
- NCT number
- NCT02254265
- Sponsor
- Sun Pharmaceutical Industries Limited
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2015-05-01
- Enrollment
- 455
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.